Napolitano, S.
Matrone, N.
Muddassir, A. L.
Martini, G.
Sorokin, A.
De Falco, V.
Giunta, E. F.
Ciardiello, D.
Martinelli, E.
Belli, V.
Furia, M.
Kopetz, S.
Morgillo, F.
Ciardiello, F.
Troiani, T.
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (AIRC IG 18972)
Regione Campania (I-CURE)
Article History
Received: 1 October 2019
Accepted: 29 November 2019
First Online: 16 December 2019
Ethics approval and consent to participate
: The present study was approved by the Animal Ethics of the University of Campania “Luigi Vanvitelli” Animal Care and Use Committee and by the Animal Ethics Committee of MD Anderson Cancer center, Houston (TX).
: Not applicable.
: TT: advisory board for Amgen, Bayer, Merck, Novartis, Roche, Sanofi. FM: advisory board for Lilly, MSD. EM: advisory board for Amgen, Bayer, Merck, Roche, Sanofi, Servier, Biocartis and expert opinion for ESMO (European Society of Medical Oncology). FDV: advisory board for Amgen, Lilly, Roche, Celgene. FC: advisory board for Merck, Roche, Amgen, Bayer, Servier, Symphogen,Pfizer and research funding from Roche, Merck, Amgen, Bayer, Ipsen. SK: advisory board fees from Amal Therapeutics, Amgen, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Boston Biomedical, Eli Lilly, EMD Serono, Holy Stone Healthcare, Karyopharm Therapeutics, Merck, Novartis, Roche, and Symphogen, grant support, paid to M.D. Anderson Cancer Center, from AstraZeneca, holding stock options in Navire Pharma, and receiving lecture fees from Pierre Fabre Pharmaceuticals.SN, NM, ALM, GM, AS, VDF, EFG, DC, VB, MF, declare no competing conflict of interest regarding the following manuscript.